Abstract:Corneal diseases are the second major cause of blindness worldwide. Corneal neovascularization (NV) is one of the most common pathologies in corneal diseases, leading to vision loss or even blindness. However, even though different treatments for corneal NV are available, a safe and effective therapy remains to be an unmet medical challenge. MicroRNAs (miRNAs) play roles in regulating more than half of all protein-coding genes in mammals including those involved with angiogenesis. We hypothesize that modulating expression of angiogenesis related miRNAs might be an effective approach for treating corneal NV. To this end, we first set out to identify target miRNAs that play roles in corneal NV using Nanostring technologies and the classic alkali-burn induced corneal NV mouse model. Among 618 mouse miRNAs profiled, we found 35 up-regulated and 3 down-regulated miRNAs in the neovascularized corneas, which were confirmed by qRT-PCR. We selected miR-184 and miR-204, two miRNAs that were down-regulated u003e 10-folds in neovascularized corneas, as our candidate targets to test the concept of in vivo gene delivery for therapeutic miRNA to treat corneal NV. As recombinant adeno-associated virus (rAAV) holds promise for highly efficient and safe in vivo gene delivery to different target tissues in a serotype dependent manner, we opted to evaluate 14 serotypes of rAAV.EGFP for gene transfer efficiency in mouse corneas by eye drops (ED), intra-stromal (IS) and subconjunctival (SC) injections to search for the suitable vector(s) for delivering miRNA therapeutics to the corneas. Among the 4 leading serotype vectors (i.e. rAAVrh.8, rh.10, rh.39 and rh.43) identified, we chose rAAVrh.10 for overexpressing pri miR-184 and pri miR-204 in the corneas with alkali-burn induced corneal NV. rAAVrh.10-mediated overexpression of miR-184 or miR-204 by IS and SC injections but not ED efficiently inhibited angiogenesis and was efficacious and safe for either prevention (IS) or treatment (SC) of corneal NV. We further invested potential target genes and pathways to elucidate the anti-angiogenic mechanism of these two miRNA therapeutics. We revealed that the anti-angiogenic effect of rAAV.pri-miR-184 was achieved by targeting Fzd4 gene, thus suppressing the canonical Wnt signaling, a well-known pathway playing vital roles in angiogenesis; while rAAV.pri-miR-204 exerted its anti-angiogenic effect by targeting angiopoietin-1 gene (Angpt1), a well-acknowledged pro-angiogenic factor. Meanwhile, the transcriptome analysis is under the way to search for novel gene targets of the miRNA therapeutics. Our study has great clinical relevance and demonstrated, for the first time, that miRNA-targeted novel therapeutics that can be delivered as either rAAV or synthetic nucleic acid drugs (i.e. miRNA mimics and antagomir) might offer an additional efficacious and safe clinical option for treating corneal NV and other angiogenesis-related diseases including age-related macular edema (AMD) and cancer.

AAV-Mediated EPO Gene Reduction Inhibits Choroidal Neovascularization

Reduction of Laser-Induced Choroidal Neovascularization in Mice With Erythropoietin RNA Interference

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA

Stable Inhibition of Choroidal Neovascularization by Adeno-Associated Virus 2/8-Vectored Bispecific Molecules

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a mouse model of age-related macular degeneration

739. rAAV Delivered MicroRNA Therapeutics Towards Efficacious Treatment of Corneal Neovascularization

586. Development of Anti-Angiogenic Mirna Therapeutics for Corneal Neovascularization

Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody

Periocular Gene Transfer of Pigment Epithelium-Derived Factor Inhibits Choroidal Neovascularization in a Human-Sized Eye

Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration

Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyes

Inactivation of Adenosine Receptor 2A Suppresses Endothelial-to-mesenchymal Transition and Inhibits Subretinal Fibrosis in Mice

Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies Without Inducing Retinal Vasculitis

Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration

Effects of Topic Delivery of an Inhibitor of Serine Racemase on Laser-Induced Choroidal Vasculopathy

Intravenous injection of l-aspartic acid β-hydroxamate attenuates choroidal neovascularization via anti-VEGF and anti-inflammation.

Intravenous Route to Choroidal Neovascularization by Macrophage-Disguised Nanocarriers for Mtor Modulation

“One Stone and Two Birds” Strategy to Treat Neovascular Age-Related Macular Degeneration by a Novel Retinoid Drug, EYE-101

Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization